Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.
In patients that developed a chronic renal failure the augmentation in tryptophan degradation is reflected in the increase in plasma metabolites of kynurenine pathway. Hemodialysis is one of therapeutic approaches that significantly reduce all plasma kynurenine metabolites in uremic patients. In spite of haemodialysis, plasma concentration of kynurenine, kynurenic acid, 3-hydroxykynurenine, anthranilic acid, xanthurenic acid and quinolinic acid were still elevated in uremic patients in comparison with healthy volunteers. These data shows significant disturbances in kynurenine metabolism in uremic patients. Accumulation of these substances in uremic blood is capable to account for certain uremic symptoms.
Pawlak
D
D
Department of Pharmacodynamics, Medical Academy, Bialystok, Poland. dariuszpawlak@poczta.onet.pl
Pawlak
K
K
Malyszko
J
J
Mysliwiec
M
M
Buczko
W
W
D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007736:Kynurenic Acid / Q000378:metabolism; D007737:Kynurenine / Q000031:analogs & derivatives* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017378:Quinolinic Acid / Q000378:metabolism; D006435:Renal Dialysis; D014364:Tryptophan / Q000378:metabolism; D014511:Uremia / Q000378:metabolism* / Q000628:therapy; D014977:Xanthurenates / Q000378:metabolism; D062367:ortho-Aminobenzoates / Q000378:metabolism
D014977:Xanthurenates; D062367:ortho-Aminobenzoates; C031385:anthranilic acid; C005045:3-hydroxykynurenine; D007737:Kynurenine; C028330:xanthurenic acid; D014364:Tryptophan; D017378:Quinolinic Acid; D007736:Kynurenic Acid